56
Views
2
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

Rituximab for refractory Wegener’s granulomatosis

KEOGH KA, YTTERBERG SR, FERVENZA FC et al.: Rituximab for refractory Wegener’s granulomatosis: report of a prospective, open-label pilot trial. Am. J. Respir. Crit. Care Med. (2006) 173(2):180-187.

Pages 1115-1117 | Published online: 17 Aug 2006

Bibliography

  • LANGFORD CA: Wegener’s granulomatosis: current and upcoming therapies. Arthritis Res. Ther. (2003) 5(4):180-191.
  • DE GROOT K, ADU D, SAVAGE CO: The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol. Dial. Transplant. (2001) 16(10):2018-2027.
  • SPECKS U, FERVENZA FC, McDONALD TJ, HOGAN MC: Response of Wegener’s granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum. (2001) 44(12):2836-2840.
  • SNELLER MC: Rituximab and Wegener’s granulomatosis: are B cells a target in vasculitis treatment? Arthritis Rheum. (2005) 52(1):1-5.
  • KEOGH KA, YTTERBERG SR, FERVENZA FC et al.: Rituximab for refractory Wegener’s granulomatosis: report of a prospective, open-label pilot trial. Am. J. Respir. Crit. Care Med. (2006) 173(2):180-187.
  • STONE JH, HOFFMAN GS, MERKEL PA et al.: A disease-specific activity index for Wegener’s granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum. (2001) 44(4):912-920.
  • KEOGH KA, WYLAM ME, STONE JH, SPECKS U: Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. (2005) 52(1):262-268.
  • STASI R, STIPA E, POETA GD et al.: Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford) (2006) (In Press).
  • ERIKSSON P: Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J. Intern. Med. (2005) 257(6):540-548.
  • BIRCK R, WARNATZ K, LORENZ HM et al.: 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. J. Am. Soc. Nephrol. (2003) 14(2):440-447.
  • SCHMITT WH, BIRCK R, HEINZEL PA et al.: Prolonged treatment of refractory Wegener’s granulomatosis with 15-deoxyspergualin: an open study in seven patients. Nephrol. Dial. Transplant. (2005) 20(6):1083-1092.
  • BARTOLUCCI P, RAMANOELINA J, COHEN P et al.: Efficacy of the anti-TNF-α antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) (2002) 41(10):1126-1132.
  • THE WEGENER’S GRANULOMATOSIS ETANERCEPT TRIAL RESEARCH GROUP: Etanercept plus standard therapy for Wegener’s granulomatosis. N. Engl. J. Med. (2005) 352(4):351-361.
  • SCHMITT WH, HAGEN EC, NEUMANN I et al.: Treatment of refractory Wegener’s granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int. (2004) 65(4):1440-1448.

Website

  • http://www.orpha.net/data/patho/GB/ uk-WG.pdf GUILLEVIN L, MAHR A: Wegener’s Granulomatosis. Orphanet encyclopaedia (2004).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.